Literature DB >> 25956577

Impact of Total Lymph Node Count on Staging and Survival After Neoadjuvant Chemoradiation Therapy for Rectal Cancer.

Matthew D Hall1, Timothy E Schultheiss2, David D Smith3, Marwan G Fakih4, Joseph Kim5, Jeffrey Y C Wong2, Yi-Jen Chen2.   

Abstract

PURPOSE: Current guidelines recommend that a minimum of 12 lymph nodes (LNs) be dissected to accurately stage rectal cancer patients. Neoadjuvant chemoradiation therapy (CRT) decreases the number of LNs retrieved at surgery. The purpose of this study was to assess the impact of the number of LNs dissected on overall survival (OS) for localized rectal cancer patients treated with neoadjuvant CRT.
METHODS: Treatment data were obtained on all patients treated for rectal cancer (2000-2013) in the National Oncology Data Alliance™, a proprietary database of merged tumor registries. Eligible patients were treated with neoadjuvant CRT followed by surgery and had complete data on number of positive LNs, number of LNs examined, and treatment dates (n = 4565).
RESULTS: Hazard ratios for OS decreased sequentially with increasing number of LNs examined until a maximum benefit was achieved with examination of eight LNs. On multivariate analysis, age, sex, race, marital status, grade, ypT stage, ypN stage, type of surgery, margin status, presence of pathologically confirmed metastasis at surgery, and number of LNs examined were significant predictors of OS.
CONCLUSIONS: Examination of eight or more LNs in rectal cancer patients treated with neoadjuvant CRT resulted in accurate staging and assignment into prognostic groups with an ensuing improvement in OS by stage. This study suggests that eight LNs is the threshold for an adequate lymph node dissection after neoadjuvant CRT.

Entities:  

Mesh:

Year:  2015        PMID: 25956577     DOI: 10.1245/s10434-015-4585-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  Association of certification, improved quality and better oncological outcomes for rectal cancer in a specialized colorectal unit.

Authors:  Annika Jacob; Wolfgang Albert; Thomas Jackisch; Christiane Jakob; Anja Sims; Helmut Witzigmann; Sören Torge Mees; Sigmar Stelzner
Journal:  Int J Colorectal Dis       Date:  2020-11-09       Impact factor: 2.571

2.  What Is the Minimum Number of Examined Lymph Nodes After Neoadjuvant Therapy in Rectal Cancer?

Authors:  Peng Gao; Yongxi Song; Yuchong Yang; Shan Zhao; Yu Sun; Jingxu Sun; Xiaowan Chen; Zhenning Wang
Journal:  J Gastrointest Surg       Date:  2018-02-21       Impact factor: 3.452

3.  A retrospective study on the impact of the number of resected lymph nodes on the survival outcome of stage IV rectal cancer patients after preoperative therapy.

Authors:  Kexiang Xi; Hui Yu; Kexing Xi
Journal:  J Gastrointest Oncol       Date:  2020-10

4.  Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.

Authors:  Erhan Akgun; Cemil Caliskan; Osman Bozbiyik; Tayfun Yoldas; Basak Doganavsargil; Serdar Ozkok; Timur Kose; Bulent Karabulut; Nevra Elmas; Omer Ozutemiz
Journal:  BJS Open       Date:  2022-09-02

5.  Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy.

Authors:  Jianyuan Song; Zhuhong Chen; Daxin Huang; Yimin Wu; Zhuangbin Lin; Pan Chi; Benhua Xu
Journal:  Cancer Manag Res       Date:  2020-08-18       Impact factor: 3.989

6.  Number of retrieved lymph nodes is an independent prognostic factor after total gastrectomy for patients with stage III gastric cancer: propensity score matching analysis of a multi-institution dataset.

Authors:  Shogo Hayashi; Mitsuro Kanda; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2018-11-27       Impact factor: 7.370

7.  Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.

Authors:  Stefan Münch; Daniel Habermehl; Ayman Agha; Claus Belka; Stephanie E Combs; Renate Eckel; Helmut Friess; Alexander Gerbes; Natascha C Nüssler; Wolfgang Schepp; Roland M Schmid; Wolfgang Schmitt; Gabriele Schubert-Fritschle; Bernhard Weber; Jens Werner; Jutta Engel
Journal:  Strahlenther Onkol       Date:  2017-10-25       Impact factor: 3.621

8.  Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Authors:  Yaqi Wang; Menglong Zhou; Jianing Yang; Xiaoyang Sun; Wei Zou; Zhiyuan Zhang; Jing Zhang; Lijun Shen; Lifeng Yang; Zhen Zhang
Journal:  Cancer Med       Date:  2019-06-28       Impact factor: 4.452

9.  The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Authors:  Juan Zhou; Wen-Wen Zhang; San-Gang Wu; Zhen-Yu He; Jia-Yuan Sun; Yan Wang; Qiong-Hua Chen
Journal:  Cancer Manag Res       Date:  2017-07-18       Impact factor: 3.989

10.  Fat clearance and conventional fixation identified ypN0 rectal cancers following intermediate neoadjuvant radiotherapy have similar long-term outcomes.

Authors:  Nan Chen; Ting-Ting Sun; Zhong-Wu Li; Yun-Feng Yao; Lin Wang; Ai-Wen Wu
Journal:  World J Gastrointest Oncol       Date:  2019-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.